These findings further implicate KEAP1 mutations as functionally significant mutations in thyroid cancer, directly show their role in promoting tumorigenic cellular phenotypes across distinct genetic backgrounds, and position them as a potential therapeutic target in this disease. This evidence concerns the gene KEAP1 and thyroid gland carcinoma.